Skip to main content
Syndax study for leukemia candidate SNDX-5613 advances

Syndax Pharmaceuticals announced it can now advance on plans for its open-label Phase I/II study to assess its small molecule inhibitor candidate SNDX-5613 in patients with relapsed/refractory acute leukemia. The trial's primary endpoint is the rate of complete remission in three expansion cohorts.

Full Story: